🇺🇸 FDA
Patent

US 12421292

Anti-DLL3 chimeric antigen receptors and uses thereof

granted A61KA61K2039/505A61K2239/31

Quick answer

US patent 12421292 (Anti-DLL3 chimeric antigen receptors and uses thereof) held by Legend Biotech Ireland Limited expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Legend Biotech Ireland Limited
Grant date
Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K38/00